Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$8.63 - $15.52 $31.8 Million - $57.2 Million
-3,682,877 Reduced 88.7%
469,023 $4.16 Million
Q2 2022

Aug 15, 2022

SELL
$8.59 - $20.77 $337,251 - $815,450
-39,261 Reduced 0.94%
4,151,900 $52.5 Million
Q1 2022

May 16, 2022

BUY
$15.52 - $35.65 $2.5 Million - $5.75 Million
161,161 Added 4.0%
4,191,161 $79.3 Million
Q4 2021

Feb 14, 2022

SELL
$28.89 - $35.33 $4.55 Million - $5.56 Million
-157,449 Reduced 3.76%
4,030,000 $141 Million
Q3 2021

Nov 15, 2021

SELL
$35.66 - $42.94 $7.28 Million - $8.77 Million
-204,235 Reduced 4.65%
4,187,449 $153 Million
Q2 2021

Aug 16, 2021

SELL
$23.7 - $39.27 $7.56 Million - $12.5 Million
-318,791 Reduced 6.77%
4,391,684 $172 Million
Q1 2021

May 14, 2021

SELL
$27.01 - $36.8 $25,119 - $34,224
-930 Reduced 0.02%
4,710,475 $133 Million
Q4 2020

Feb 16, 2021

SELL
$27.51 - $34.36 $2.58 Million - $3.22 Million
-93,784 Reduced 1.95%
4,711,405 $151 Million
Q3 2020

Nov 13, 2020

SELL
$25.8 - $34.61 $4.03 Million - $5.4 Million
-156,071 Reduced 3.15%
4,805,189 $155 Million
Q2 2020

Aug 14, 2020

BUY
$17.65 - $28.05 $1.87 Million - $2.97 Million
105,716 Added 2.18%
4,961,260 $137 Million
Q1 2020

May 15, 2020

BUY
$15.19 - $29.51 $3.92 Million - $7.62 Million
258,158 Added 5.62%
4,855,544 $86.7 Million
Q4 2019

Feb 18, 2020

BUY
$17.17 - $25.95 $6.27 Million - $9.48 Million
365,374 Added 8.63%
4,597,386 $115 Million
Q3 2019

Nov 14, 2019

BUY
$17.84 - $22.69 $55.6 Million - $70.7 Million
3,117,330 Added 279.66%
4,232,012 $75.5 Million
Q2 2019

Aug 14, 2019

BUY
$22.0 - $31.78 $14.4 Million - $20.8 Million
654,600 Added 142.28%
1,114,682 $24.5 Million
Q1 2019

May 15, 2019

BUY
$21.27 - $30.58 $9.79 Million - $14.1 Million
460,082 New
460,082 $14.1 Million

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $2.35B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Capital International, Inc. Portfolio

Follow Capital International, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Capital International, Inc. with notifications on news.